表紙
市場調查報告書

新的疫苗輸送設備市場:2019-2030年

Novel Vaccine Delivery Devices Market, 2019-2030

出版商 ROOTS ANALYSIS 商品編碼 915452
出版日期 內容資訊 英文 403 Pages
商品交期: 最快1-2個工作天內
價格
新的疫苗輸送設備市場:2019-2030年 Novel Vaccine Delivery Devices Market, 2019-2030
出版日期: 2019年11月30日內容資訊: 英文 403 Pages
簡介

本報告提供新的疫苗輸送設備的市場調查,疫苗及疫苗輸送方法趨勢,新的輸送設備的主要類型和概要,新設備提供的候選疫苗,設備開發經營者的簡介,各種區分的市場規模的變化、預測,專家的見解等彙整資料,為您概述為以下內容。

第1章 序文

第2章 摘要整理

第3章 簡介

  • 概要
  • 疫苗
    • 分類
    • 主要零組件
    • 表現系統
  • 疫苗輸送
  • 主要課題
  • 新的疫苗輸送方法
    • 自動注射器
    • 生物分解性植入
    • 臉頰、舌下疫苗輸送系統
    • 電穿孔 (電子穿孔) 無針注射系統
    • 吸入、經肺疫苗輸送系統
    • 噴射注射器
    • 顯微注射系統
    • 新的口服製劑
  • 未來展望

第4章 市場環境

  • 概要
  • 已上市疫苗
  • 臨床階段的疫苗
  • 新的疫苗輸送設備
    • 各設備類型
    • 各投藥途徑
    • 各藥物輸送機制
    • 疫苗給藥類型
    • 疫苗給藥速度
    • 各自我給藥的可能性
    • 各音訊&視覺回饋的可用性
    • 各設備實用性
    • 各針類型
    • 各開發階段
  • 新的疫苗輸送設備開發者
    • 各開發者類型
    • 各成立年份
    • 各企業規模
    • 各地區

第5章 設備的競爭分析

第6章 技術的有效性分析

第7章 新的疫苗輸送設備:有前途的疫苗候補

  • 概要
  • 已上市疫苗
    • 電穿孔 (電子穿孔) 無針注射系統
    • 噴射注射器
    • 微針貼片
    • 經鼻子輸送系統
    • 口服液體製劑輸送系統
    • 口服固體製劑輸送系統
    • 預填充式注射器
  • 臨床階段的疫苗
    • 電穿孔 (電子穿孔) 無針注射系統
    • 噴射注射器
    • 微針貼片
    • 經鼻子輸送系統
    • 口服液體製劑輸送系統
    • 口服固體製劑輸送系統
    • 預填充式注射器

第8章 企業簡介

  • 概要
  • 3M
  • Becton Dickinson
  • Consort Medical
  • D'Antonio Consultants International
  • Enesi Pharma
  • Ichor Medical
  • Iconovo
  • Inovio Pharmaceuticals
  • PharmaJet
  • Union Medico

第9章 聯盟、合作

  • 概要
  • 聯盟模式
  • 聯盟、合作分析:各種區分

第10章 SWOT分析

第11章 市場規模、市場機會分析

  • 概要
  • 市場預測
  • 市場預測:各設備類型
  • 市場預測:各投藥途徑
  • 市場預測:各疫苗類型
  • 市場預測:各地區

第12章 專家的見解

第13章 總論

第14章 附錄:圖表資料

第15章 附錄:企業、組織清單

目錄

Overview:

According to experts, the global vaccines market is anticipated to generate revenues worth USD 100 billion by 2025. Data presented by the WHO indicates that the current global vaccination coverage is nearly 85%; this is believed to be responsible for preventing close to three million deaths from diseases, such as diphtheria, tetanus, whooping cough and measles. Recent global immunization records indicate that more than 115 million children were immunized against diphtheria, tetanus and pertussis in 2018. Given the rate at which the global population is growing, the demand for vaccines is likely to increase significantly. However, biopharmaceutical developers are plagued by concerns related to storage and handling of such preventive / therapeutic products. One commonly reported issue is related to vaccine administration. Despite the success of conventional delivery approaches, which rely on the intramuscular and subcutaneous routes of administration, the present scenario dictates that further improvements are required in order to deal with challenges related to large scale immunization initiatives. Some of the commonly reported disadvantages of the conventional (parenteral) mode of delivery include pain during administration, risk of cross contamination, needlestick injuries, and inaccurate dosing.

Of late, there has been an evident shift in interest to non-invasive immunization methods, which include oral, intranasal and transdermal modes of administration. Currently, many biopharmaceutical companies and clinical research institutes are engaged in the development of novel vaccine delivery systems, taking into consideration the specific requirements of large scale immunization initiatives. As a result, significant efforts have been put into the development of drug delivery technologies / devices, such as microneedle patches, electroporation-based needle free injection systems, jet injectors, inhalation-based delivery systems, biodegradable implants and certain novel types of oral delivery systems. It is worth highlighting that most of the aforementioned systems are specifically being designed to facilitate pain-free administration of vaccines and allow self-administration. Vaccine developers are also attempting to devise ways to make such products more stable so as to eliminate the need for cold chain in transporting such products. Given the pace of innovation in this field, it is anticipated that the novel vaccine delivery devices market is likely to witness radical changes in the coming years.

Scope of the Report:

The “Novel Vaccine Delivery Devices Market, 2019-2030” report features an extensive study of the current landscape and the likely future opportunities associated with novel vaccine delivery devices, over the next 10-12 years. Amongst other elements, the report includes:

  • A detailed assessment of the overall novel vaccine delivery devices market landscape, featuring an elaborate list of device developers and analysis based on a number of relevant parameters, such as year of establishment, company size, geographical location, type of device (autoinjectors, microneedle patches, jet injectors, dry powder inhalers, microinjectors, nasal delivery systems, pen injectors, biodegradable implants, electroporation-based needle free injection systems and novel oral delivery systems), route of administration (subcutaneous, transdermal, intramuscular, intradermal, inhalation, intranasal, and oral), drug delivery mechanism (mechanical, electrical and miscellaneous), nature of vaccine administration (invasive and non-invasive), speed of administration (fast, moderate and slow), self- administration potential, provisions for audio / visual feedback, device usability (disposable and reusable), type of needle (needleless, fixed needle, detachable needle, and hidden needle), and current development status of novel vaccine delivery systems (preclinical / discovery, clinical and marketed).
  • A detailed competitiveness analysis of novel vaccine delivery devices, taking into consideration the supplier power (based on the year of establishment of developer company) and key product specifications (such as route of administration, device usability, drug delivery mechanism, availability of needle safety system, speed of administration, self-administration potential, provisions for audio / visual feedback, nature of administration, cold chain requirement and current status of development).
  • An analysis evaluating the effectiveness of various vaccines delivery devices in order to compare their respective strengths and capabilities based on a variety of relevant parameters, such as type of active ingredient, dosage form, route of administration, target disease indication and target patient population.
  • A detailed list of marketed and pipeline vaccine candidates that are anticipated to be developed in combination with novel vaccine delivery devices in the near future, featuring analysis based on parameters, such as type of active ingredient, dosage form, route of administration, target disease indication and target patient population.
  • Elaborate profiles of prominent product developers engaged in this domain; each profile features a brief overview of the company, its financial information (if available), information on its product portfolio, recent developments and an informed future outlook.
  • An analysis of recent collaborations and partnership agreements inked in this domain since 2014, including details of deals that were / are focused on novel vaccine delivery devices. The partnerships captured in the report were analyzed on the basis of year of establishment, type of agreement, type of device, type of vaccine, type of active ingredient and target disease indication.
  • A discussion on important, industry-specific trends, key market drivers and challenges, under a comprehensive SWOT framework, featuring a qualitative Harvey ball analysis that highlights the relative impact of each SWOT parameter on the overall market.

One of the key objectives of the report was to estimate the existing market size and assess potential future growth opportunities for novel vaccine delivery devices. Based on various parameters, such as number of marketed / pipeline products, price of devices (for commercially available products only) and estimated annual adoption rate, we have developed an informed estimate on the likely evolution of the market over the period 2019-2030. In addition, we have provided the likely distribution of the current and forecasted opportunities across [A] type of device (electroporation-based needle free injection systems, oral delivery systems, nasal delivery systems, jet injectors, microneedle patches and microinjectors), [B] route of administration (oral, intramuscular, intranasal, intradermal and subcutaneous), [C] type of vaccine (Bivalent Oral Polio Vaccine, BCG Vaccine, DTP-HepB-Hib Vaccine, Pneumococcal Conjugate Vaccine, Influenza Vaccine, Measles Vaccine, Tetanus-Diphtheria Vaccine and Others) and [D] key geographical regions (North America, Europe, Asia and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:

  • Michael Schrader, Chief Executive Officer and Founder, Vaxess Technologies
  • Mikael Ekstrom and Roger Lassing, Vice President, Business Development, Iconovo
  • Henry King, Market Intelligence and Business Development Manager, Innoture

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Chapter Outlines:

Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the current scenario within the novel vaccine delivery devices market and describes its evolution in the short-mid term and long term.

Chapter 3 provides a general introduction to vaccines along with information on classification of such preventive / therapeutic products. It also includes an overview of the various expression systems used in the development and manufacturing of vaccines and a discussion on various routes of administration. It features brief descriptions of various novel vaccine delivery devices and concludes with a discussion on the existing challenges and future trends that are likely to impact this emerging market segment.

Chapter 4 provides a detailed overview of the overall landscape of novel vaccine delivery devices that are developed / being developed for administration of various vaccines. It features an in-depth analysis of the devices, based on a number of parameters, such as details on type of device (autoinjectors, microneedle patches, jet injectors, dry powder inhalers, microinjectors, nasal delivery systems, pen injectors, biodegradable implants, electroporation-based needle free injection systems and novel oral delivery systems), route of administration (subcutaneous, transdermal, intramuscular, intradermal, inhalation, intranasal, and oral), drug delivery mechanism (mechanical, electrical and miscellaneous), nature of vaccine administration (invasive and non-invasive), speed of administration (fast, moderate and slow), self-administration potential, provisions for audio / visual feedback, device usability (disposable and reusable), type of needle (needleless, fixed needle, detachable needle, and hidden needle), and current development status of novel vaccine delivery systems (preclinical / discovery, clinical and marketed). In addition, the chapter provides information on drug developer(s), highlighting year of establishment, location of headquarters and strength of employee base.

Chapter 5 features a product competitiveness analysis of novel vaccine delivery devices, based on the supplier power and product specifications. The analysis was designed to enable stakeholder companies to compare their existing capabilities within and beyond their respective peer groups and identify opportunities to achieve a competitive edge in the industry.

Chapter 6 provides detailed assessment to evaluate the effectiveness of various vaccines delivery devices to compare their strengths and capabilities for vaccine administration; the analysis is based on a variety of relevant parameters, such as type of active ingredient, dosage form, route of administration, target disease indication and target patient population.

Chapter 7 presents a list of marketed and pipeline vaccines that are likely to be considered for delivery via novel vaccine delivery devices in the future. The list was compiled considering various parameters, such as type of active ingredient, dosage form, route of administration, target disease indication and target patient population. For the purpose of this analysis, we collated a list of over 490 marketed and clinical vaccines. The likelihood of delivery via novel vaccine delivery devices in the future was estimated using the weighted average of the aforementioned parameters.

Chapter 8 provides detailed profiles of key novel vaccine delivery device developers. Each profile presents a brief overview of the company, its financial information (if available), information on its product portfolio, recent developments and an informed future outlook.

Chapter 9 features an elaborate analysis and discussion of the various collaborations and partnerships related to the novel vaccine delivery devices, which have been inked amongst players. It includes a brief description of the purpose of the partnership models (including R&D agreements, product development, licensing, distribution, research agreements, manufacturing agreements, acquisitions, product development and commercialization and others) that have been adopted by the stakeholders in this domain, since 2014. It consists of a schematic representation showcasing the players that have forged the maximum number of alliances. Furthermore, we have provided a world map representation of the deals inked in this field, highlighting those that have been established within and across different continents.

Chapter 10 provides a discussion on important industry-specific trends, key market drivers and challenges, under a SWOT framework, featuring a qualitative Harvey ball analysis, that highlights the relative impact of each SWOT parameter on the overall medical device label manufacturing industry.

Chapter 11 presents an insightful market forecast analysis, highlighting the future potential of novel vaccine delivery devices market, till the year 2030. We have segregated the opportunity of novel vaccine delivery devices on the basis of different types of device (electroporation-based needle free injection systems, oral delivery systems, nasal delivery systems, jet injectors, microneedle patches and microinjectors), route of administration (oral, intramuscular, intranasal, intradermal and subcutaneous, type of vaccine (Bivalent Oral Polio Vaccine, BCG Vaccine, DTP-HepB-Hib Vaccine, Pneumococcal Conjugate Vaccine, Influenza Vaccine, Measles Vaccine, Tetanus-Diphtheria Vaccine and Others) and key geographical regions (North America, Europe, Asia and rest of the world).

Chapter 12 is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the details of interviews held with Michael Schrader (Chief Executive Officer and Founder, Vaxess Technologies), Mikael Ekstrom and Roger Lassing (Vice President, Business Development, Iconovo) and Henry King (Market Intelligence and Business Development Manager, Innoture).

Chapter 13 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario. Further, it captures the evolutionary trends that are likely to determine the future of this segment of the novel vaccine delivery devices industry.

Chapter 14 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 15 is an appendix, which contains a list of companies and organizations mentioned in this report.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Vaccines
    • 3.2.1. Classification of Vaccines
      • 3.2.1.1. Live, Attenuated Vaccines
      • 3.2.1.2. Inactivated Vaccines
      • 3.2.1.3. Subunit Vaccines
      • 3.2.1.4. Toxoid Vaccines
      • 3.2.1.5. DNA Vaccines
    • 3.2.2. Key Components of a Vaccine Formulation
    • 3.2.3. Expression Systems Used for Vaccine Production
      • 3.2.3.1. Embryonated Chicken Eggs and Primary Chicken Embryonic Fibroblasts (CEFs)
      • 3.2.3.2. Mammalian Expression Systems
      • 3.2.3.3. Avian Expression Systems
      • 3.2.3.4. Plant Expression Systems
      • 3.2.3.5. Bacterial Expression Systems
      • 3.2.3.6. Yeast Expression Systems
      • 3.2.3.7. Insect Expression Systems
  • 3.3. Vaccine Delivery
    • 3.3.1. Intradermal Route
    • 3.3.2. Subcutaneous Route
    • 3.3.3. Intramuscular Route
    • 3.3.4. Oral Route
    • 3.3.5. Intranasal Route
    • 3.3.6. Inhalation Route
  • 3.4. Key Challenges Associated with Vaccine Delivery
  • 3.5. Novel Approaches for Vaccine Delivery
    • 3.5.1. Autoinjectors
    • 3.5.2. Biodegradable Implants
    • 3.5.3. Buccal / Sublingual Vaccine Delivery Systems
    • 3.5.4. Electroporation-based Needle Free Injection Systems
    • 3.5.5. Inhalation / Pulmonary Vaccine Delivery Systems
    • 3.5.6. Jet Injectors
    • 3.5.7. Microinjection System
    • 3.5.8. Novel Orally Administrable Formulations
  • 3.6. Future Perspectives

4. MARKET LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. Marketed Vaccines Landscape
  • 4.3. Clinical-Stage Vaccines Landscape
  • 4.4. Novel Vaccine Delivery Devices: Overall Market Landscape
    • 4.4.1. Analysis by Type of Device
    • 4.4.2. Analysis by Route of Administration
    • 4.4.3. Analysis by Drug Delivery Mechanism
    • 4.4.4. Analysis by Nature of Vaccine Administration
    • 4.4.5. Analysis by Speed of Vaccine Administration
    • 4.4.6. Analysis by Self-Administration Potential
    • 4.4.7. Analysis by Availability of Audio / Visual Feedback
    • 4.4.8. Analysis by Device Usability
    • 4.4.9. Analysis by Type of Needle
    • 4.4.10. Analysis by Stage of Development
  • 4.5. Novel Vaccine Delivery Device Developers: Overall Market Landscape
    • 4.5.1. Analysis by Type of Developer
    • 4.5.2. Analysis by Year of Establishment
    • 4.5.3. Analysis by Company Size
    • 4.5.4. Analysis by Geographical Location

5. DEVICE COMPETITIVENESS ANALYSIS

  • 5.1. Chapter overview
  • 5.2. Assumptions and Methodology
  • 5.3. Novel Vaccine Delivery Devices: Competitive Landscape
  • 5.4. Concluding Remarks

6. TECHNOLOGY EFFECTIVENESS ANALYSIS

  • 6.1. Chapter Overview
  • 6.2. Assumptions and Key Parameters
  • 6.3. Methodology
  • 6.4. Vaccine Delivery Devices: Technology Effectiveness Analysis
    • 6.4.1. Devices for Marketed Vaccines
      • 6.4.1.1. Analysis by Type of Active Ingredient
      • 6.4.1.2. Analysis by Dosage Form
      • 6.4.1.3. Analysis by Route of Administration
      • 6.4.1.4. Analysis by Target Disease Indication
      • 6.4.1.5. Analysis by Target Patient Population
    • 6.4.2. Devices for Clinical-Stage Vaccines
      • 6.4.2.1. Analysis by Type of Active Ingredient
      • 6.4.2.2. Analysis by Dosage Form
    • 6..2.3. Analysis by Route of Administration
      • 6.4.2.4. Analysis by Target Disease Indication
      • 6.4.2.5. Analysis by Target Patient Population

7. NOVEL VACCINE DELIVERY DEVICES: LIKELY VACCINE CANDIDATES

  • 7.1. Chapter Overview
  • 7.2. Marketed Vaccines
    • 7.2.1. Electroporation-based Needle Free Injection Systems: Likely Vaccine Candidates
      • 7.2.1.1. Most Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems
      • 7.2.1.2. Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems
      • 7.2.1.3. Less Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems
      • 7.2.1.4. Least Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems
    • 7.2.2. Jet Injectors: Likely Vaccine Candidates
      • 7.2.2.1. Most Likely Candidates for Delivery via Jet Injectors
      • 7.2.2.2. Likely Candidates for Delivery via Jet Injectors
      • 7.2.2.3. Less Likely Candidates for Delivery via Jet Injectors
      • 7.2.2.4. Least Likely Candidates for Delivery via Jet Injectors
    • 7.2.3. Microneedle Patches: Likely Vaccine Candidates
      • 7.2.3.1. Most Likely Candidates for Delivery via Microneedle Patches
      • 7.2.3.2. Likely Candidates for Delivery via Microneedle Patches
      • 7.2.3.3. Less Likely Candidates for Delivery via Microneedle Patches
      • 7.2.3.4. Least Likely Candidates for Delivery via Microneedle Patches
    • 7.2.4. Nasal Delivery Systems: Likely Vaccine Candidates
      • 7.2.4.1. Most Likely Candidates for Delivery via Nasal Delivery Systems
      • 7.2.4.2. Likely Candidates for Delivery via Nasal Delivery Systems
      • 7.2.4.3. Less Likely Candidates for Delivery via Nasal Delivery Systems
      • 7.2.4.4. Least Likely Candidates for Delivery via Nasal Delivery Systems
    • 7.2.5. Oral Delivery Systems for Liquid Formulations: Likely Vaccine Candidates
      • 7.2.5.1. Most Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
      • 7.2.5.2. Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
      • 7.2.5.3. Less Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
      • 7.2.5.4. Least Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
    • 7.2.6. Oral Delivery Systems for Solid Formulations: Likely Vaccine Candidates
      • 7.2.6.1. Most Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
      • 7.2.6.2. Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
      • 7.2.6.3. Less Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
      • 7.2.6.4. Least Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
    • 7.2.7. Prefilled Syringes: Likely Vaccine Candidates
      • 7.2.7.1. Most Likely Candidates for Delivery via Prefilled Syringes
      • 7.2.7.2. Likely Candidates for Delivery via Prefilled Syringes
      • 7.2.7.3. Less Likely Candidates for Delivery via Prefilled Syringes
      • 7.2.7.4. Least Likely Candidates for Delivery via Prefilled Syringes
  • 7.3. Clinical-Stage Vaccines
    • 7.3.1. Electroporation-based Needle Free Injection Systems: Likely Vaccine Candidates
      • 7.3.1.1. Most Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems
      • 7.3.1.2. Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems
      • 7.3.1.3. Less Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems
      • 7.3.1.4. Least Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems
    • 7.3.2. Jet Injectors: Likely Vaccine Candidates
      • 7.3.2.1. Most Likely Candidates for Delivery via Jet Injectors
      • 7.3.2.2. Likely Candidates for Delivery via Jet Injectors
      • 7.3.2.3. Less Likely Candidates for Delivery via Jet Injectors
      • 7.3.2.4. Least Likely Candidates for Delivery via Jet Injectors
    • 7.3.3. Microneedle Patches: Likely Vaccine Candidates
      • 7.3.3.1. Most Likely Candidates for Delivery via Microneedle Patches
      • 7.3.3.2. Likely Candidates for Delivery via Microneedle Patches
      • 7.3.3.3. Less Likely Candidates for Delivery via Microneedle Patches
      • 7.3.3.4. Least Likely Candidates for Delivery via Microneedle Patches
    • 7.3.4. Nasal Delivery Systems: Likely Vaccine Candidates
      • 7.3.4.1. Most Likely Candidates for Delivery via Nasal Delivery Systems
      • 7.3.4.2. Likely Candidates for Delivery via Nasal Delivery Systems
      • 7.3.4.3. Less Likely Candidates for Delivery via Nasal Delivery Systems
      • 7.3.4.4. Least Likely Candidates for Delivery via Nasal Delivery Systems
    • 7.3.5. Oral Delivery Systems for Liquid Formulations: Likely Vaccine Candidates
      • 7.3.5.1. Most Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
      • 7.3.5.2. Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
      • 7.3.5.3. Less Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
      • 7.3.5.4. Least Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
    • 7.3.6. Oral Delivery Systems for Solid Formulations: Likely Vaccine Candidates
      • 7.3.6.1. Most Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
      • 7.3.6.2. Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
      • 7.3.6.3. Less Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
      • 7.3.6.4. Least Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
    • 7.3.7. Prefilled Syringes: Likely Vaccine Candidates
      • 7.3.7.1. Most Likely Candidates for Delivery via Prefilled Syringes
      • 7.3.7.2. Likely Candidates for Delivery via Prefilled Syringes
      • 7.3.7.3. Less Likely Candidates for Delivery via Prefilled Syringes
      • 7.3.7.4. Least Likely Candidates for Delivery via Prefilled Syringes

8. COMPANY PROFILES

  • 8.1. Chapter Overview
  • 8.2. 3M
    • 8.2.1. Company Overview
    • 8.2.2. Financial Information
    • 8.2.3. Product Portfolio
      • 8.2.3.1. 3M™ Hollow Microstructured Transdermal System
      • 8.2.3.2. 3M™ Solid Microneedle
    • 8.2.4. Recent Collaborations
    • 8.2.5. Future Outlook
  • 8.3. Becton Dickinson
    • 8.3.1. Company Overview
    • 8.3.2. Financial Information
    • 8.3.3. Product Portfolio
      • 8.3.3.1. BD Intevia™ Handheld Autoinjector
      • 8.3.3.2. BD Accuspray™ Nasal Spray System
    • 8.3.4. Recent Collaborations
    • 8.3.5. Future Outlook
  • 8.4. Consort Medical
    • 8.4.1. Company Overview
    • 8.4.2. Financial Information
    • 8.4.3. Technology Overview
    • 8.4.4. Product Portfolio
      • 8.4.4.1. Autoinjectors
        • 8.4.4.1.1. Syrina
        • 8.4.4.1.2. OTS Autoinjector
      • 8.4.4.2. Nasal Delivery System
    • 8.4.5. Recent Collaborations
    • 8.4.6. Future Outlook
  • 8.5. D'Antonio Consultants International
    • 8.5.1. Company Overview
    • 8.5.2. Product Portfolio
      • 8.5.2.1. LectraJet® HS High Speed Jet Injection
      • 8.5.2.2. LectraJet® M3 RA Needle-free Injection
      • 8.5.2.3. Multi-Channel Jet Injector
      • 8.5.2.4. LectraJet® M4 RA
  • 8.6. Enesi Pharma
    • 8.6.1. Company Overview
    • 8.6.2. Technology Overview
    • 8.6.3. Product Portfolio
      • 8.6.3.1. Enesi ImplaVax®
      • 8.6.3.2. Solid Dose Injector
    • 8.6.4. Recent Collaborations
    • 8.6.5. Future Outlook
  • 8.7. Ichor Medical
    • 8.7.1. Company Overview
    • 8.7.2. Financial Information
    • 8.7.3. Product Portfolio
      • 8.7.3.1. TriGrid® Delivery System
    • 8.7.4. Recent Collaborations
    • 8.7.5. Future Outlook
  • 8.8. Iconovo
    • 8.8.1. Company Overview
    • 8.8.2. Financial Information
    • 8.8.3. Product Portfolio
      • 8.8.3.1. ICOres
      • 8.8.3.2. ICOone
      • 8.8.3.3. ICOcap
      • 8.8.3.4. ICOpre
    • 8.8.4. Recent Collaborations
    • 8.8.5. Future Outlook
  • 8.9. Inovio Pharmaceuticals
    • 8.9.1. Company Overview
    • 8.9.2. Financial Information
    • 8.9.3. Product Portfolio
      • 8.9.3.1. ZetaJet®
      • 8.9.3.2. Biojector® 2000
      • 8.9.3.2. CELLECTRA® Electroporation Delivery Device
    • 8.9.4. Recent Collaborations
    • 8.9.5. Future Outlook
  • 8.10. PharmaJet
    • 8.10.1. Company Overview
    • 8.10.2. Financial Information
    • 8.10.3. Product Portfolio
      • 8.10.3.1. PharmaJet Stratis® Needle-free Injector
      • 8.10.3.2. PharmaJet Tropis® Intradermal Injection
    • 8.10.4. Recent Collaborations
    • 8.10.5. Future Outlook
  • 8.11. Union Medico
    • 8.11.1. Company Overview
    • 8.11.2. Product Portfolio
      • 8.11.2.1. 45° Autoinjector
      • 8.11.2.2. 90° Autoinjector
      • 8.11.2.3. SuperGrip Autoinjector
      • 8.11.2.4. Exclusive Autoinjector
    • 8.11.3. Recent Collaborations
    • 8.11.4. Future Outlook

9. PARTNERSHIPS AND COLLABORATIONS

  • 9.1. Chapter Overview
  • 9.2. Partnership Models
  • 9.3. Novel Vaccine Delivery Devices: Partnerships and Collaborations
    • 9.3.1. Analysis by Year of Partnership
    • 9.3.2. Analysis by Type of Partnership
    • 9.3.3. Analysis by Type of Device
    • 9.3.4. Analysis by Type of Partnership and Type of Device
    • 9.3.5. Analysis by Type of Vaccine and Type of Device
    • 9.3.6. Analysis by Type of Active Ingredient
    • 9.3.7. Analysis by Target Disease Indication
    • 9.3.8. Popular Vaccine Delivery Devices: Analysis by Number of Partnerships
    • 9.3.9. Most Active Industry Players: Analysis by Number of Partnerships
    • 9.3.10. Geographical Analysis
      • 9.3.10.1. Intercontinental and Intracontinental Agreements

10. SWOT ANALYSIS

  • 10.1. Chapter Overview
  • 10.2. Strengths
  • 10.3. Weaknesses
  • 10.4. Opportunities
  • 10.5. Threats
  • 10.6. Concluding Remarks

11. MARKET SIZING AND OPPORTUNITY ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Forecast Methodology and Key Assumptions
  • 11.3. Global Novel Vaccine Delivery Devices Market, 2019-2030
  • 11.4. Global Novel Vaccine Delivery Devices Market: Distribution by Type of Device, 2019-2030
  • 11.5. Global Novel Vaccine Delivery Devices Market: Distribution by Route of Administration, 2019-2030
  • 11.6. Global Novel Vaccine Delivery Devices Market: Distribution by Type of Vaccine, 2019-2030
  • 11.7. Global Novel Vaccine Delivery Devices Market: Distribution by Regions, 2019-2030
    • 11.7.1. Novel Vaccine Delivery Devices Market in North America, 2019-2030
      • 11.7.1.1. Novel Vaccine Delivery Devices Market in North America: Distribution by Type of Device, 2019-2030
      • 11.7.1.2. Novel Vaccine Delivery Devices Market in North America: Distribution by Route of Administration, 2019-2030
      • 11.7.1.3. Novel Vaccine Delivery Devices Market in North America: Distribution by Type of Vaccine, 2019-2030
    • 11.7.2. Novel Vaccine Delivery Devices Market in Europe, 2019-2030
      • 11.7.2.1. Novel Vaccine Delivery Devices Market in Europe: Distribution by Type of Device, 2019-2030
      • 11.7.2.2. Novel Vaccine Delivery Devices Market in Europe: Distribution by Route of Administration, 2019-2030
      • 11.7.2.3. Novel Vaccine Delivery Devices Market in Europe: Distribution by Type of Vaccine, 2019-2030
    • 11.7.3. Novel Vaccine Delivery Devices Market in Asia Pacific, 2019-2030
      • 11.7.3.1. Novel Vaccine Delivery Devices Market in Asia Pacific: Distribution by Type of Device, 2019-2030
      • 11.7.3.2. Novel Vaccine Delivery Devices Market in Asia Pacific: Distribution by Route of Administration, 2019-2030
      • 11.7.3.3. Novel Vaccine Delivery Devices Market in Asia Pacific: Distribution by Type of Vaccine, 2019-2030
    • 11.7.4. Novel Vaccine Delivery Devices Market in Rest of the World, 2019-2030
      • 11.7.4.1. Novel Vaccine Delivery Devices Market in Rest of the World: Distribution by Type of Device, 2019-2030
      • 11.7.4.2. Novel Vaccine Delivery Devices Market in Rest of the World: Distribution by Route of Administration, 2019-2030
      • 11.7.4.3. Novel Vaccine Delivery Devices Market in Rest of the World: Distribution by Type of Vaccine, 2019-2030

12. EXECUTIVE INSIGHTS

  • 12.1. Chapter Overview
  • 12.2. Vaxess Technologies
    • 12.2.1. Company Snapshot
    • 12.2.2. Interview Transcript: Michael Schrader, Chief Executive Officer and Founder
  • 12.3. Iconovo
    • 12.3.1. Company Snapshot
    • 12.3.2. Interview Transcript: Mikael Ekstrom and Roger Lassing, Vice Presidents, Business Development
  • 12.3. Innoture
    • 12.3.1. Company Snapshot
    • 12.3.2. Interview Transcript: Henry King, Market Intelligence and Business Development Manager

13. CONCLUDING REMARKS

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figuers

  • Figure 3.1 Difference between Vaccines and Small Molecules
  • Figure 3.2 Classification of Vaccines
  • Figure 3.3 Therapeutic Delivery through the Skin
  • Figure 3.4 Common Routes of Administration Used for Vaccines
  • Figure 3.5 Novel Vaccine Delivery Devices
  • Figure 4.1 Novel Vaccine Delivery Devices: Distribution by Type of Device
  • Figure 4.2 Novel Vaccine Delivery Devices: Distribution by Route of Administration
  • Figure 4.3 Novel Vaccine Delivery Devices: Distribution by Type of Device and Route of Administration
  • Figure 4.4 Novel Vaccine Delivery Devices: Distribution by Drug Delivery Mechanism
  • Figure 4.5 Novel Vaccine Delivery Devices: Distribution by Type of Device and Drug Delivery Mechanism
  • Figure 4.6 Novel Vaccine Delivery Devices: Distribution by Nature of Vaccine Administration
  • Figure 4.7 Novel Vaccine Delivery Devices: Distribution by Type of Device and Nature of Vaccine Administration
  • Figure 4.8 Novel Vaccine Delivery Devices: Distribution by Speed of Vaccine Administration
  • Figure 4.9 Novel Vaccine Delivery Devices: Distribution by Type of Device and Speed of Vaccine Administration
  • Figure 4.10 Novel Vaccine Delivery Devices: Distribution by Self-Administration Potential
  • Figure 4.11 Novel Vaccine Delivery Devices: Distribution by Type of Device and Self-Administration Potential
  • Figure 4.12 Novel Vaccine Delivery Devices: Distribution by Availability of Audio / Visual Feedback
  • Figure 4.13 Novel Vaccine Delivery Devices: Distribution by Type of Device and Availability of Audio / Visual Feedback
  • Figure 4.14 Novel Vaccine Delivery Devices: Distribution by Device Usability
  • Figure 4.15 Novel Vaccine Delivery Devices: Distribution by Type of Device and Device Usability
  • Figure 4.16 Novel Vaccine Delivery Devices: Distribution by Type of Needle
  • Figure 4.17 Novel Vaccine Delivery Devices: Distribution by Type of Device and Type of Needle
  • Figure 4.18 Novel Vaccine Delivery Devices: Distribution by Stage of Development
  • Figure 4.19 Novel Vaccine Delivery Devices: Distribution by Type of Device and Stage of Development
  • Figure 4.20 Novel Vaccine Delivery Device Developers: Distribution by Type of Developer
  • Figure 4.21 Novel Vaccine Delivery Device Developers: Distribution by Year of Establishment
  • Figure 4.22 Novel Vaccine Delivery Device Developers: Distribution by Company Size
  • Figure 4.23 Novel Vaccine Delivery Device Developers: Distribution by Geographical Location
  • Figure 5.1 Device Competitiveness Analysis: Novel Vaccine Delivery Devices
  • Figure 6.1 Technology Effectiveness of Devices for Marketed Vaccines: Analysis by Type of Active Ingredient
  • Figure 6.2 Technology Effectiveness of Devices for Marketed Vaccines: Analysis by Dosage Form
  • Figure 6.3 Technology Effectiveness of Devices for Marketed Vaccines: Analysis by Route of Administration
  • Figure 6.4 Technology Effectiveness of Devices for Marketed Vaccines: Analysis by Target Disease Indication
  • Figure 6.5 Technology Effectiveness of Devices for Marketed Vaccines: Analysis by Target Patient Population
  • Figure 6.6 Technology Effectiveness of Devices for Clinical-Stage Vaccines: Analysis by Type of Active Ingredient
  • Figure 6.7 Technology Effectiveness of Devices for Clinical-Stage Vaccines: Analysis by Dosage Form
  • Figure 6.8 Technology Effectiveness of Devices for Clinical-Stage Vaccines: Analysis by Route of Administration
  • Figure 6.9 Technology Effectiveness of Devices for Clinical-Stage Vaccines: Analysis by Target Disease Indication
  • Figure 6.10 Technology Effectiveness of Devices for Clinical-Stage Vaccines: Analysis by Target Patient Population
  • Figure 8.1 3M: Annual Revenues, 2015-Q2 2019 (USD Billion)
  • Figure 8.2 3M™ Hollow Microstructured Transdermal System: Approval Process
  • Figure 8.3 3M™ Hollow Microstructured Transdermal System: Advantages
  • Figure 8.4 3M™ Solid Microneedle: Features
  • Figure 8.5 Becton Dickinson: Annual Revenues, 2014-Q3 2019 (USD Billion)
  • Figure 8.6 Consort Medical: Annual Revenues, 2015-Q2 2019 (USD Million)
  • Figure 8.7 Consort Medical: Syrina® Autoinjectors
  • Figure 8.8 LectraJet® Technology and Devices
  • Figure 8.9 LectraJet® HS High Speed Jet Injection: Features
  • Figure 8.10 ImplaVax® Technology: Components
  • Figure 8.11 ImplaVax®: Features
  • Figure 8.12 Ichor Medical Systems: Annual Revenues, 2014-2018 (USD Million)
  • Figure 8.13 Ichor Medical Systems: Electroporation Process
  • Figure 8.14 Iconovo: Dry Powder Inhalers
  • Figure 8.15 Inovio Pharmaceutical: Annual Revenues, 2014-Q3 2019 (USD Million)
  • Figure 8.16 dMAb™ Technology: Advantages
  • Figure 8.17 PhrmaJet Tropis® Intradermal Injection: Administration Steps
  • Figure 8.18 Union Medico: Types of 45°Autoinjector
  • Figure 8.19 Union Medico: Components of 45°/R Autoinjector
  • Figure 8.20 Union Medico: Types of 90° Autoinjectors
  • Figure 8.21 Union Medico: Components of Exclusive Autoinjector
  • Figure 9.1 Partnerships and Collaborations: Cumulative Distribution by Year, 2014-2019
  • Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 9.3 Partnerships and Collaborations: Distribution by Type of Device
  • Figure 9.4 Partnerships and Collaborations: Distribution by Year and Type of Device
  • Figure 9.5 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Device
  • Figure 9.6 Partnerships and Collaborations: Distribution by Type of Vaccine and Type of Device
  • Figure 9.7 Partnerships and Collaborations: Distribution by Type of Active Ingredient
  • Figure 9.8 Partnerships and Collaborations: Distribution by Target Disease Indication
  • Figure 9.9 Partnerships and Collaborations: Popular Vaccine Delivery Devices
  • Figure 9.10 Partnerships and Collaborations: Most Active Players
  • Figure 9.11 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
  • Figure 10.1 Novel Vaccine Delivery Devices: SWOT Analysis
  • Figure 10.2 Comparison of SWOT Factors: Harvey Ball Analysis
  • Figure 11.1. Global Novel Vaccine Delivery Devices Market, 2019-2030 (USD Million)
  • Figure 11.2 Global Novel Vaccine Delivery Devices Market: Distribution by Type of Device, 2019-2030 (USD Million)
  • Figure 11.3 Global Novel Vaccine Delivery Devices Market: Distribution by Route of Administration, 2019-2030 (USD Million)
  • Figure 11.4 Global Novel Vaccine Delivery Devices Market: Distribution by Type of Vaccine, 2019-2030 (USD Million)
  • Figure 11.5 Global Novel Vaccine Delivery Devices Market: Distribution by Regions, 2019-2030 (USD Billion)
  • Figure 11.6 Novel Vaccine Delivery Devices Market in North America, 2019-2030 (USD Million)
  • Figure 11.7 Novel Vaccine Delivery Devices Market in North America: Distribution by Type of Device, 2019-2030 (USD Million)
  • Figure 11.8 Novel Vaccine Delivery Devices Market in North America: Distribution by Route of Administration, 2019-2030 (USD Million)
  • Figure 11.9 Novel Vaccine Delivery Devices Market in North America: Distribution by Type of Vaccine, 2019-2030 (USD Million)
  • Figure 11.10 Novel Vaccine Delivery Devices Market in Europe, 2019-2030 (USD Million)
  • Figure 11.11 Novel Vaccine Delivery Devices Market in Europe: Distribution by Type of Device, 2019-2030 (USD Million)
  • Figure 11.12 Novel Vaccine Delivery Devices Market in Europe: Distribution by Route of Administration, 2019-2030 (USD Million)
  • Figure 11.13 Novel Vaccine Delivery Devices Market in Europe: Distribution by Type of Vaccine, 2019-2030 (USD Million)
  • Figure 11.14 Novel Vaccine Delivery Devices Market in Asia Pacific, 2019-2030 (USD Million)
  • Figure 11.15 Novel Vaccine Delivery Devices Market in Asia Pacific: Distribution by Type of Device, 2019-2030 (USD Million)
  • Figure 11.16 Novel Vaccine Delivery Devices Market in Asia Pacific: Distribution by Route of Administration, 2019-2030 (USD Million)
  • Figure 11.17 Novel Vaccine Delivery Devices Market in Asia Pacific: Distribution by Type of Vaccine, 2019-2030 (USD Million)
  • Figure 11.18 Novel Vaccine Delivery Devices Market in Rest of the World, 2019-2030 (USD Million)
  • Figure 11.19 Novel Vaccine Delivery Devices Market in Rest of the World: Distribution by Type of Device, 2019-2030 (USD Million)
  • Figure 11.20 Novel Vaccine Delivery Devices Market in Rest of the World: Distribution by Route of Administration, 2019-2030 (USD Million)
  • Figure 11.21 Novel Vaccine Delivery Devices Market in Rest of the World: Distribution by Type of Vaccine, 2019-2030 (USD Million)

List Of Tables

  • Table 3.1. Classification of Vaccines
  • Table 3.2. Live Attenuated Vaccines: Commonly Reported Adverse Events
  • Table 3.3. Inactivated Vaccines: Commonly Reported Adverse Events
  • Table 3.4. Subunit Vaccines: Commonly Reported Adverse Events
  • Table 3.5. Toxoid Vaccines: Commonly Reported Adverse Events
  • Table 3.6. Vaccine Excipients and Associated Functions
  • Table 3.7. Routes of Administration and Delivery Devices for Vaccines
  • Table 3.8. Common Pediatric Vaccines and Affiliated Routes of Administration
  • Table 4.1. List of Marketed Vaccines
  • Table 4.2. List of Clinical-Stage Vaccines
  • Table 4.3. Novel Vaccine Delivery Devices: List of Available / Under Development Products
  • Table 4.4. Novel Vaccine Delivery Devices: List of Developers
  • Table 7.1. Marketed Vaccines: Likely Candidates for Delivery via Novel Vaccine Delivery Devices
  • Table 7.2. Marketed Vaccines: Most Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems
  • Table 7.3. Marketed Vaccines: Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems
  • Table 7.4. Marketed Vaccines: Less Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems
  • Table 7.5. Marketed Vaccines: Least Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems
  • Table 7.6. Marketed Vaccines: Most Likely Candidates for Delivery via Jet Injectors
  • Table 7.7. Marketed Vaccines: Likely Candidates for Delivery via Jet Injectors
  • Table 7.8. Marketed Vaccines: Less Likely Candidates for Delivery via Jet Injectors
  • Table 7.9. Marketed Vaccines: Least Likely Candidates for Delivery via Jet Injectors
  • Table 7.10. Marketed Vaccines: Most Likely Candidates for Delivery via Microneedle Patches
  • Table 7.11. Marketed Vaccines: Likely Candidates for Delivery via Microneedle Patches
  • Table 7.12. Marketed Vaccines: Less Likely Candidates for Delivery via Microneedle Patches
  • Table 7.13. Marketed Vaccines: Least Likely Candidates for Delivery via Microneedle Patches
  • Table 7.14. Marketed Vaccines: Most Likely Candidates for Delivery via Nasal Delivery Systems
  • Table 7.15. Marketed Vaccines: Likely Candidates for Delivery via Nasal Delivery Systems
  • Table 7.16. Marketed Vaccines: Less Likely Candidates for Delivery via Nasal Delivery Systems
  • Table 7.17. Marketed Vaccines: Least Likely Candidates for Delivery via Nasal Delivery Systems
  • Table 7.18. Marketed Vaccines: Most Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
  • Table 7.19. Marketed Vaccines: Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
  • Table 7.20. Marketed Vaccines: Less Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
  • Table 7.21. Marketed Vaccines: Least Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
  • Table 7.22. Marketed Vaccines: Most Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
  • Table 7.23. Marketed Vaccines: Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
  • Table 7.24. Marketed Vaccines: Less Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
  • Table 7.25. Marketed Vaccines: Least Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
  • Table 7.26. Marketed Vaccines: Most Likely Candidates for Delivery via Prefilled Syringes
  • Table 7.27. Marketed Vaccines: Likely Candidates for Delivery via Prefilled Syringes
  • Table 7.28. Marketed Vaccines: Less Likely Candidates for Delivery via Prefilled Syringes
  • Table 7.29. Marketed Vaccines: Least Likely Candidates for Delivery via Prefilled Syringes
  • Table 7.30. Clinical-Stage Vaccines: Likely Candidates for Delivery via Novel Vaccine Delivery Devices
  • Table 7.31. Clinical-Stage Vaccines: Most Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems
  • Table 7.32. Clinical-Stage Vaccines: Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems
  • Table 7.33. Clinical-Stage Vaccines: Less Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems
  • Table 7.34. Clinical-Stage Vaccines: Least Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems
  • Table 7.35. Clinical-Stage Vaccines: Most Likely Candidates for Delivery via Jet Injectors
  • Table 7.36. Clinical-Stage Vaccines: Likely Candidates for Delivery via Jet Injectors
  • Table 7.37. Clinical-Stage Vaccines: Less Likely Candidates for Delivery via Jet Injectors
  • Table 7.38. Clinical-Stage Vaccines: Least Likely Candidates for Delivery via Jet Injectors
  • Table 7.39. Clinical-Stage Vaccines: Most Likely Candidates for Delivery via Microneedle Patches
  • Table 7.40. Clinical-Stage Vaccines: Likely Candidates for Delivery via Microneedle Patches
  • Table 7.41. Clinical-Stage Vaccines: Less Likely Candidates for Delivery via Microneedle Patches
  • Table 7.42. Clinical-Stage Vaccines: Least Likely Candidates for Delivery via Microneedle Patches
  • Table 7.43. Clinical-Stage Vaccines: Most Likely Candidates for Delivery via Nasal Delivery Systems
  • Table 7.44. Clinical-Stage Vaccines: Likely Candidates for Delivery via Nasal Delivery Systems
  • Table 7.45. Clinical-Stage Vaccines: Less Likely Candidates for Delivery via Nasal Delivery Systems
  • Table 7.46. Clinical-Stage Vaccines: Least Likely Candidates for Delivery via Nasal Delivery Systems
  • Table 7.47. Clinical-Stage Vaccines: Most Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
  • Table 7.48. Clinical-Stage Vaccines: Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
  • Table 7.49. Clinical-Stage Vaccines: Less Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
  • Table 7.50. Clinical-Stage Vaccines: Least Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
  • Table 7.51. Clinical-Stage Vaccines: Most Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
  • Table 7.52. Clinical-Stage Vaccines: Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
  • Table 7.53. Clinical-Stage Vaccines: Less Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
  • Table 7.54. Clinical-Stage Vaccines: Least Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
  • Table 7.55. Clinical-Stage Vaccines: Most Likely Candidates for Delivery via Prefilled Syringes
  • Table 7.56. Clinical-Stage Vaccines: Likely Candidates for Delivery via Prefilled Syringes
  • Table 7.57. Clinical-Stage Vaccines: Less Likely Candidates for Delivery via Prefilled Syringes
  • Table 7.58. Clinical-Stage Vaccines: Least Likely Candidates for Delivery via Prefilled Syringes
  • Table 8.1. Novel Vaccine Delivery Devices: List of Companies Profiled
  • Table 8.2. 3M: Recent Collaborations
  • Table 8.3. 3M: Future Outlook
  • Table 8.4. Becton Dickinson: Vaccine Delivery Devices Portfolio
  • Table 8.5. Becton Dickinson: Recent Collaborations
  • Table 8.6. Becton Dickinson: Future Outlook
  • Table 8.7. Consort Medical: Recent Collaborations
  • Table 8.8. Consort Medical: Future Outlook
  • Table 8.9. Enesi Pharma: Recent Collaborations
  • Table 8.10. Enesi Pharma: Future Outlook
  • Table 8.11. Ichor Medical Systems: Recent Collaborations
  • Table 8.12. Ichor Medical Systems: Future Outlook
  • Table 8.13. Iconovo: Recent Collaborations
  • Table 8.14. Iconovo: Future Outlook
  • Table 8.15. Inovio Pharmaceuticals: Recent Collaborations
  • Table 8.16. Inovio Pharmaceuticals: Future Outlook
  • Table 8.17. PharmaJet: Recent Collaborations
  • Table 8.18. PharmaJet: Future Outlook
  • Table 8.19. Union Medico: Comparison of 45° Autoinjectors
  • Table 8.20. Union Medico: Comparison of 90° Autoinjectors
  • Table 9.1. Novel Vaccine Delivery Devices: Partnerships and Collaborations, 2014-2019 (till September)
  • Table 12.1. Vaxess Technologies: Company Snapshot
  • Table 12.2. Iconovo: Company Snapshot
  • Table 12.3. Innoture: Company Snapshot
  • Table 13.1. Novel Vaccine Delivery Devices: Summary of the Competitive Insights
  • Table 14.1. Novel Vaccine Delivery Devices: Distribution by Type of Device
  • Table 14.2. Novel Vaccine Delivery Devices: Distribution by Route of Administration
  • Table 14.3. Novel Vaccine Delivery Devices: Distribution by Type of Device and Route of Administration
  • Table 14.4. Novel Vaccine Delivery Devices: Distribution by Drug Delivery Mechanism
  • Table 14.5. Novel Vaccine Delivery Devices: Distribution by Type of Device and Drug Delivery Mechanism
  • Table 14.6. Novel Vaccine Delivery Devices: Distribution by Nature of Vaccine Administration
  • Table 14.7. Novel Vaccine Delivery Devices: Distribution by Type of Device and Nature of Vaccine Administration
  • Table 14.8. Novel Vaccine Delivery Devices: Distribution by Speed of Vaccine Administration
  • Table 14.9. Novel Vaccine Delivery Devices: Distribution by Type of Device and Speed of Vaccine Administration
  • Table 14.10. Novel Vaccine Delivery Devices: Distribution by Self-Administration Potential
  • Table 14.11. Novel Vaccine Delivery Devices: Distribution by Type of Device and Self-Administration Potential
  • Table 14.12. Novel Vaccine Delivery Devices: Distribution by Availability of Audio / Visual Feedback
  • Table 14.13. Novel Vaccine Delivery Devices: Distribution by Type of Device and Availability of Audio / Visual Feedback
  • Table 14.14. Novel Vaccine Delivery Devices: Distribution by Device Usability
  • Table 14.15. Novel Vaccine Delivery Devices: Distribution by Type of Device and Device Usability
  • Table 14.16. Novel Vaccine Delivery Devices: Distribution by Type of Needle
  • Table 14.17. Novel Vaccine Delivery Devices: Distribution by Type of Device and Type of Needle
  • Table 14.18. Novel Vaccine Delivery Devices: Distribution by Stage of Development
  • Table 14.19. Novel Vaccine Delivery Devices: Distribution by Type of Device and Stage of Development
  • Table 14.20. Novel Vaccine Delivery Device Developers: Distribution by Type of Developer
  • Table 14.21. Novel Vaccine Delivery Device Developers: Distribution by Year of Establishment
  • Table 14.22. Novel Vaccine Delivery Device Developers: Distribution by Company Size
  • Table 14.23. Novel Vaccine Delivery Device Developers: Distribution by Geographical Location
  • Table 14.24. Technology Effectiveness of Devices for Marketed Vaccines: Analysis by Type of Active Ingredient
  • Table 14.25. Technology Effectiveness of Devices for Marketed Vaccines: Analysis by Dosage Form
  • Table 14.26. Technology Effectiveness of Devices for Marketed Vaccines: Analysis by Route of Administration
  • Table 14.27. Technology Effectiveness of Devices for Marketed Vaccines: Analysis by Target Disease Indication
  • Table 14.28. Technology Effectiveness of Devices for Marketed Vaccines: Analysis by Target Patient Population
  • Table 14.29. Technology Effectiveness of Devices for Clinical-Stage Vaccines: Analysis by Type of Active Ingredient
  • Table 14.30. Technology Effectiveness of Devices for Clinical-Stage Vaccines: Analysis by Dosage Form
  • Table 14.31. Technology Effectiveness of Devices for Clinical-Stage Vaccines: Analysis by Route of Administration
  • Table 14.32. Technology Effectiveness of Devices for Clinical-Stage Vaccines: Analysis by Target Disease Indication
  • Table 14.33. Technology Effectiveness of Devices for Clinical-Stage Vaccines: Analysis by Target Patient Population
  • Table 14.34. 3M: Annual Revenues, 2015-Q2 2019 (USD Billion)
  • Table 14.35. Becton Dickinson: Annual Revenues, 2014-Q3 2019 (USD Billion)
  • Table 14.36. Consort Medical: Annual Revenues, 2015-Q2 2019 (USD Million)
  • Table 14.37. Ichor Medical Systems: Annual Revenues, 2014-2018 (USD Million)
  • Table 14.38. Inovio Pharmaceutical: Annual Revenues, 2014-Q3 2019 (USD Million)
  • Table 14.39. Partnerships and Collaborations: Cumulative Distribution by Year, 2014-2019
  • Table 14.40. Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 14.41. Partnerships and Collaborations: Distribution by Type of Device
  • Table 14.42. Partnerships and Collaborations: Distribution by Year and Type of Device
  • Table 14.43. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Device
  • Table 14.44. Partnerships and Collaborations: Distribution by Type of Vaccine and Type of Device
  • Table 14.45. Partnerships and Collaborations: Distribution by Type of Active Ingredient
  • Table 14.46. Partnerships and Collaborations: Distribution by Target Disease Indication
  • Table 14.47. Partnerships and Collaborations: Popular Vaccine Delivery Devices
  • Table 14.48. Partnerships and Collaborations: Most Active Players
  • Table 14.49. Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
  • Table 14.50. Global Novel Vaccine Delivery Devices Market, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
  • Table 14.51. Global Novel Vaccine Delivery Devices Market: Distribution by Type of Device, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
  • Table 14.52. Global Novel Vaccine Delivery Devices Market: Distribution by Route of Administration, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
  • Table 14.53. Global Novel Vaccine Delivery Devices Market: Distribution by Type of Vaccine, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
  • Table 14.54. Global Novel Vaccine Delivery Devices Market: Distribution by Regions, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
  • Table 14.55. Novel Vaccine Delivery Devices Market in North America, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
  • Table 14.56. Novel Vaccine Delivery Devices Market in North America: Distribution by Type of Device, 2019-2030 (USD Million)
  • Table 14.57. Novel Vaccine Delivery Devices Market in North America: Distribution by Route of Administration, 2019-2030 (USD Million)
  • Table 14.58. Novel Vaccine Delivery Devices Market in North America: Distribution by Type of Vaccine, 2019-2030 (USD Million)
  • Table 14.59. Novel Vaccine Delivery Devices Market in Europe, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
  • Table 14.60. Novel Vaccine Delivery Devices Market in Europe: Distribution by Type of Device, 2019-2030 (USD Million)
  • Table 14.61. Novel Vaccine Delivery Devices Market in Europe: Distribution by Route of Administration, 2019-2030 (USD Million)
  • Table 14.62. Novel Vaccine Delivery Devices Market in Europe: Distribution by Type of Vaccine, 2019-2030 (USD Million)
  • Table 14.63. Novel Vaccine Delivery Devices Market in Asia Pacific, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
  • Table 14.64. Novel Vaccine Delivery Devices Market in Asia Pacific: Distribution by Type of Device, 2019-2030 (USD Million)
  • Table 14.65. Novel Vaccine Delivery Devices Market in Asia Pacific: Distribution by Route of Administration, 2019-2030 (USD Million)
  • Table 14.66. Novel Vaccine Delivery Devices Market in Asia Pacific: Distribution by Type of Vaccine, 2019-2030 (USD Million)
  • Table 14.67. Novel Vaccine Delivery Devices Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
  • Table 14.68. Novel Vaccine Delivery Devices Market in Rest of the World: Distribution by Type of Device, 2019-2030 (USD Million)
  • Table 14.69. Novel Vaccine Delivery Devices Market in Rest of the World: Distribution by Route of Administration, 2019-2030 (USD Million)
  • Table 14.70. Novel Vaccine Delivery Devices Market in Rest of the World: Distribution by Type of Vaccine, 2019-2030 (USD Million)

Listed Companies

The following companies and organizations have been mentioned in the report:

  • 1. 3M
  • 2. Abbott
  • 3. AbCellera
  • 4. ABO Pharmaceuticals
  • 5. AC Immune
  • 6. Accelovance
  • 7. AdminMed
  • 8. Aduro Biotech
  • 9. Advagene Biopharma
  • 10. Advaxis
  • 11. Aelix Therapeutics
  • 12. Aeras
  • 13. Aesica Pharmaceuticals
  • 14. Affinivax
  • 15. Affiris
  • 16. Agenus
  • 17. AgResearch
  • 18. Aimmune Therapeutics
  • 19. Aivita Biomedical
  • 20. AJ Vaccines
  • 21. Aktiv-Dry
  • 22. Alopexx Vaccine
  • 23. AlphaVax
  • 24. Altimmune
  • 25. American Association for Cancer Research
  • 26. Anhui Zhifei Longcom Biologic Pharmacy
  • 27. Animal Health Board
  • 28. Antares Pharma
  • 29. Apogee Technology
  • 30. Araclon Biotech
  • 31. Archivel Farma
  • 32. Argos Therapeutics
  • 33. Astellas Pharma
  • 34. AstraZeneca
  • 35. Australian Respiratory and Sleep Medicine Institute
  • 36. AVIR Green Hills Biotechnology
  • 37. Axon Neuroscience
  • 38. Barr Labs
  • 39. Battelle
  • 40. Bavarian Nordic
  • 41. Baylor College of Medicine
  • 42. BCN Peptides
  • 43. Becton Dickinson
  • 44. Beijing Center for Disease Control and Prevention
  • 45. Beijing Institute of Biological Products
  • 46. Beijing Minhai Biotechnology
  • 47. Beijing Tricision Biotherapeutics
  • 48. Beijing Wantai Biological Pharmacy Enterprise
  • 49. Beijing Zhifei Lvzhu Biopharmaceutical
  • 50. Bernhard Nocht Institute for Tropical Medicine
  • 51. Bharat Biotech International
  • 52. Bill and Melinda Gates Foundation
  • 53. Bilthoven Biologicals
  • 54. Biofabri
  • 55. Bioject Medical Technologies
  • 56. Biological E
  • 57. Bio-Manguinhos
  • 58. Biomedical Advanced Research and Development Authority
  • 59. Biomedizinische Forschungs
  • 60. BioNTech
  • 61. BiondVax Pharmaceuticals
  • 62. Bioneedle Technologies Group
  • 63. Biontech
  • 64. BioSerenTach
  • 65. Birla Institute of Technology and Science
  • 66. Boehringer Ingelheim
  • 67. Boryung Pharmaceutical
  • 68. BrightPath Biotherapeutics
  • 69. Bristol-Myers Squibb
  • 70. Bul Bio-National Center of Infectious and Parasitic Diseases
  • 71. Cadila Health Care
  • 72. Cancer Insight
  • 73. Cancer Research UK
  • 74. Cancer Vaccines Charitable Trust
  • 75. CanSino Biologics
  • 76. Capital Medical University
  • 77. Celerion
  • 78. Celgene
  • 79. Celldex Therapeutics
  • 80. Centers for Disease Control and Prevention
  • 81. Center for Genetic Engineering and Biotechnology
  • 82. Center for HIV/AIDS Vaccine Immunology (CHAVI)
  • 83. Changhai Hospital
  • 84. Charite University
  • 85. Chengdu Institute of Biological Products
  • 86. Children's Hospital of Philadelphia
  • 87. Chinese PLA General Hospital
  • 88. Chiron Behring Vaccines
  • 89. Chumakov Federal Scientific Center for Research & Development of Immune-And Biological Products
  • 90. City of Hope Medical Center
  • 91. College of Medicine and Allied Health Sciences
  • 92. Consort Medical
  • 93. Corium
  • 94. CosMED Pharmaceutical
  • 95. Cromos Pharma
  • 96. CSL
  • 97. CureVac
  • 98. Curevo
  • 99. DALI Medical Devices
  • 100. Dana-Farber Cancer Institute
  • 101. D'Antonio Consultants International
  • 102. Dartmouth-Hitchcock Medical Center
  • 103. Debiotech
  • 104. Department of Health and Human Services
  • 105. Duke University
  • 106. Dutch Cancer Society
  • 107. Dynavax Technologies
  • 108. E Ink Holdings
  • 109. E3D Elcam Drug Delivery Devices
  • 110. Earle A. Chiles Research Institute
  • 111. Elios Therapeutics
  • 112. Emergent BioSolutions
  • 113. Emergent Product Development
  • 114. EMMES
  • 115. Emory University
  • 116. Enesi Pharma
  • 117. EuBiologics
  • 118. Federal State Budgetary Scientific Institution
  • 119. FFF Enterprises
  • 120. FHI 360
  • 121. FIT Biotech
  • 122. Flextronics International
  • 123. Flinders University
  • 124. FluGen
  • 125. Forschungszentrum Jülich
  • 126. Fourth Military Medical University
  • 127. Fred Hutchinson Cancer Research Center
  • 128. Fuda Cancer Hospital
  • 129. FUJIFILM Pharmaceuticals
  • 130. Gamaleya Research Institute of Epidemiology and Microbiology
  • 131. GC Pharma
  • 132. Genentech
  • 133. GeneOne Life Science
  • 134. Genetic Immunity
  • 135. Genexine
  • 136. Genocea Biosciences
  • 137. Georgia Institute of Technology
  • 138. GeoVax
  • 139. German Cancer Research Center
  • 140. Gilead Sciences
  • 141. GlaxoSmithKline
  • 142. GlobeImmune
  • 143. GPO-MBP
  • 144. Gradalis
  • 145. Grameen Foundation
  • 146. Green Cross
  • 147. GreenSignal Bio Pharma
  • 148. Gritstone Oncology
  • 149. Guangdong 999 Brain Hospital
  • 150. Guangzhou Anjie Biomedical Technology
  • 151. Guangzhou Trinomab Biotech
  • 152. Gynecologic Oncology Group
  • 153. H. Lee Moffitt Cancer Center and Research Institute
  • 154. Hadassah Medical Organization
  • 155. Haffkine Bio Pharmaceutical
  • 156. Hemispherx Biopharma
  • 157. HIV Vaccine Trials Network
  • 158. Hookipa Biotech
  • 159. Hoosier Cancer Research Network
  • 160. Hualan Biological Bacterin
  • 161. Ichor Medical Systems
  • 162. Iconovo
  • 163. IDRI
  • 164. Il-Yang Pharmaceutical
  • 165. Immatics
  • 166. Immune Biosolutions
  • 167. Immune Design
  • 168. Immunitor
  • 169. ImmunoCellular Therapeutics
  • 170. Immunomic Therapeutics
  • 171. ImmuPatch
  • 172. Imperial College London
  • 173. Imugene
  • 174. INCYTO
  • 175. Infectious Disease Research Institute
  • 176. Innoture Medical Technology
  • 177. Inovio Pharmaceuticals
  • 178. Inserm
  • 179. Institut Pasteur
  • 180. Institute of Clinical Research
  • 181. Institute of Vaccines and Medical Biologicals
  • 182. International Centre for Diarrheal Disease Research
  • 183. International Vaccine Institute
  • 184. Intravacc
  • 185. Invectys
  • 186. IPPOX Foundation
  • 187. ISA Pharmaceuticals
  • 188. Istari Oncology
  • 189. Janssen Biotech
  • 190. Japan BCG Laboratory
  • 191. Jiangsu Jindike Biotechnology
  • 192. Jiangsu Province Centers for Disease Control and Prevention
  • 193. Jinan University Guangzhou
  • 194. JN-International Medical
  • 195. Johns Hopkins Bloomberg School of Public Health
  • 196. Jonsson Comprehensive Cancer Center
  • 197. Jurong Centers for Disease Control and Prevention
  • 198. Kenya Medical Research Institute
  • 199. Korean Center for Disease Control and Prevention
  • 200. Kurve Technology
  • 201. Laboratory Corporation of America
  • 202. Leiden University Medical Center
  • 203. Leidos
  • 204. LG Chem
  • 205. Likang Life Sciences
  • 206. LimmaTech Biologics
  • 207. London School of Hygiene and Tropical Medicine
  • 208. Louisiana State University Health Sciences Center in New Orleans
  • 209. LTS
  • 210. Ludwig Institute for Cancer Research
  • 211. Ludwig-Maximilians-University, Charite University
  • 212. LuMind Research Down Syndrome Foundation
  • 213. Madison Vaccines
  • 214. Mahidol University
  • 215. Marker Therapeutics
  • 216. Massachusetts General Hospital
  • 217. MassBiologics
  • 218. Mayo Clinic
  • 219. MCM Vaccine
  • 220. McMaster University
  • 221. MD Anderson Cancer Center
  • 222. Medicago
  • 223. Medical International Technologies
  • 224. Medical Research Council
  • 225. Medical University Innsbruck
  • 226. Medical University of Vienna
  • 227. Medigen Vaccine Biologics
  • 228. MedImmune
  • 229. MEDRx
  • 230. MedsForAll
  • 231. Memorial Sloan Kettering Cancer Center
  • 232. Mercia Pharma
  • 233. Merck
  • 234. Microdermics
  • 235. Micron Biomedical
  • 236. Micropoint Technologies
  • 237. MIKROGEN
  • 238. Military Infectious Diseases Research Program
  • 239. Minervax
  • 240. Ministry of Health of the Russian Federation
  • 241. Ministry of Health and Sanitation of Sierra Leone
  • 242. Moffitt Clinical Research Network
  • 243. Mogam Biotechnology Research Institute
  • 244. Moore Medical
  • 245. MSD Wellcome Trust Hilleman Laboratories
  • 246. Mundipharma
  • 247. Mylan
  • 248. NanoPass Technologies
  • 249. NantKwest
  • 250. National Cancer Institute
  • 251. National Institute for Health Research
  • 252. National Institute for Medical Research
  • 253. National Institute of Allergy and Infectious Diseases
  • 254. National Institute of Biomedical Imaging and Bioengineering
  • 255. National Institute on Aging
  • 256. National Institutes of Health
  • 257. National Pediatric Cancer Foundation
  • 258. National University Hospital
  • 259. Naval Medical Research Center
  • 260. Nemaura Pharma
  • 261. Nemera
  • 262. Neon Therapeutics
  • 263. Norwegian Institute of Public Health
  • 264. Nova Immunotherapeutics
  • 265. Nova Laboratories
  • 266. Novartis
  • 267. Novavax
  • 268. NovInject
  • 269. Nuance Designs
  • 270. OncBioMune Pharmaceuticals
  • 271. OncoPep
  • 272. OncoTherapy Science
  • 273. Oncovir
  • 274. Olymvax Biopharmaceuticals
  • 275. OptiNose
  • 276. Organon Teknika
  • 277. Osaka University
  • 278. Ospedale San Raffaele
  • 279. Oswaldo Cruz Foundation
  • 280. Panacea
  • 281. Parexel
  • 282. PATH
  • 283. PepTcell
  • 284. Pfizer
  • 285. PharmaJet
  • 286. PHC Injection Device Technologies
  • 287. Philipps University Marburg Medical Center
  • 288. Philips Medisize
  • 289. Picofluidics
  • 290. Plumbline Life Sciences
  • 291. Profectus BioSciences
  • 292. Prometheon Pharma
  • 293. PROSENEX Ambulatoriumbetriebs
  • 294. Proswell Medical
  • 295. Protein Sciences
  • 296. Providence Cancer Center
  • 297. Providence Health & Services
  • 298. PT Bio Farma
  • 299. Public Health England (PHE)
  • 300. Queen's University Belfast
  • 301. Research Foundation for Microbial Diseases of Osaka University
  • 302. Rising Tide Foundation
  • 303. Robbins Instruments
  • 304. Robert Koch Institut
  • 305. Romagnolo Scientific Institute for the Study and Treatment of Tumors
  • 306. Roswell Park Cancer Institute
  • 307. Royal Liverpool and Broadgreen University Hospitals NHS Trust
  • 308. Russian Academy of Sciences
  • 309. Sanaria
  • 310. Sanofi
  • 311. Scandinavian Biopharma
  • 312. Sellas Life Sciences Group
  • 313. Sementis
  • 314. Seqirus
  • 315. Serum Institute of India
  • 316. Shanghai Bovax Biotechnology
  • 317. Shanghai Houchao Biotechnology
  • 318. Shantha Biotechnics
  • 319. Shenzhen Geno-Immune Medical Institute
  • 320. Shin Nippon Biomedical Laboratories
  • 321. SHL Group
  • 322. Sidney Kimmel Comprehensive Cancer Center
  • 323. Sinovac Biotech
  • 324. SK Bioscience
  • 325. Skinject
  • 326. Stand Up To Cancer
  • 327. Stanford University
  • 328. Statens Serum Institut
  • 329. Stevanato Group
  • 330. Swiss Group for Clinical Cancer Research
  • 331. Takeda
  • 332. Task Foundation
  • 333. Teva Pharmaceutical
  • 334. Texas Children's Hospital
  • 335. The Aurum Institute
  • 336. The Clatterbridge Cancer Center
  • 337. The First Affiliated Hospital of Guangdong Pharmaceutical University
  • 338. The Immunobiological Technology Institute
  • 339. The Methodist Hospital System
  • 340. The Wistar Institute
  • 341. Themis Bioscience
  • 342. TheraJect
  • 343. Third Military Medical University
  • 344. Transgene
  • 345. Treos Bio
  • 346. Trudell Medical International
  • 347. TuBerculosis Vaccine Initiative
  • 348. UbiVac
  • 349. Union Medico
  • 350. United States Agency for International Development
  • 351. United States Army Medical Research Institute of Infectious Diseases
  • 352. United States Department of Defense
  • 353. University Health Network
  • 354. University Hospital Tuebingen
  • 355. University Medical Center Hamburg-Eppendorf
  • 356. University Medical Center Groningen
  • 357. University of Arkansas
  • 358. University of California
  • 359. University of Cape Town Lung Institute
  • 360. University of Cologne
  • 361. University of Copenhagen
  • 362. University of Florida
  • 363. University of Groningen
  • 364. University of Iowa
  • 365. University of Lausanne Hospitals
  • 366. University of Liverpool
  • 367. University of Maryland
  • 368. University of Michigan
  • 369. University of Oxford
  • 370. University of Pennsylvania
  • 371. University of Pisa
  • 372. University of Pittsburgh
  • 373. University of South Australia
  • 374. University of Southampton
  • 375. University of Sydney
  • 376. University of Washington
  • 377. University of Wisconsin
  • 378. University of Zaragoza
  • 379. US Army Medical Research and Material Command
  • 380. Vaccibody
  • 381. Vaccitech
  • 382. Valeritas
  • 383. Valneva
  • 384. Vaxart
  • 385. Vaxess Technologies
  • 386. VAXIMM
  • 387. Vaxine
  • 388. Vaxxas
  • 389. VBI Vaccines
  • 390. Vetter Pharma
  • 391. ViciniVax
  • 392. ViroStatics
  • 393. Walter Reed Army Institute of Research
  • 394. Washington University School of Medicine
  • 395. Weill Medical College of Cornell University
  • 396. West Pharmaceuticals
  • 397. World Health Organization
  • 398. World Vision of Ireland
  • 399. Wyeth Pharmaceuticals
  • 400. XEME Biopharma
  • 401. Xiamen Innovax Biotech
  • 402. Xiamen University
  • 403. Ypsomed
  • 404. Zosano Pharma